UBS Group’s PROVECTUS BIOPHARMACEUTICALS, INC. (DE) PVCT Stock Holding History

UBS Group’s Portfolio PVCT Stock Details PVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-309,214	Closed	-$31K	–	8415
2016 Q3	$31K	Buy	309,214 +100,029	+48%	+$21.8K	﹤0.01%	5910
2016 Q2	$78K	Buy	209,185 +86,906	+71%	+$33.1K	﹤0.01%	5204
2016 Q1	$47K	Buy	122,279 +3,203	+3%	+$1.32K	﹤0.01%	5564
2015 Q4	$46K	Sell	119,076 -17,108	-13%	-$8.11K	﹤0.01%	5899
2015 Q3	$78K	Sell	136,184 -36,459	-21%	-$18.7K	﹤0.01%	5443
2015 Q2	$93K	Sell	172,643 -32,852	-16%	-$26.8K	﹤0.01%	5462
2015 Q1	$168K	Sell	205,495 -39,964	-16%	-$32.9K	﹤0.01%	5016
2014 Q4	$196K	Buy	+245,459	New	+$224K	﹤0.01%	5072

Other funds holding PVCT

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

HFBOT

Home Federal Bank of Tennessee Knoxville, Tennessee $463M AUM 24.62% 1-Year Est. Return

UBS Group's PVCT Position: Q4 2016 in Review

UBS Group sold out of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) in Q4 2016, closing a stake of 309,214 shares — an estimated $31K sold.

UBS Group first reported a position in PVCT in Q4 2014 and held it in 8 quarters. The position peaked at $196K in Q4 2014. 8 funds tracked by Wall St. Rank hold PVCT as of Q4 2016.

UBS Group reported no remaining PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position as of Q4 2016 after selling out during the quarter.
UBS Group sold 309,214 PROVECTUS BIOPHARMACEUTICALS, INC. (DE) shares in Q4 2016, an estimated $31K.
UBS Group first reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in Q4 2014 and held it in 8 quarters.
UBS Group's PROVECTUS BIOPHARMACEUTICALS, INC. (DE) position peaked at $196K in Q4 2014.
8 funds tracked by Wall St. Rank held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) as of Q4 2016.

Based on UBS Group's 13F filing for Q4 2016, filed 14 Feb 2017.